Extracellular Vesicle Polymer Composition for Lesion-Targeted Tissue Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for tissue damage, including those using cells and extracellular vesicles, suffer from low integration and targeting efficiency, leading to repeated treatments and high costs, limiting the range of diseases and patients that can be treated.
Innovation Solution
A pharmaceutical composition comprising a biocompatible polymer of general formula (I) AaXxYy and at least one extracellular vesicle, which targets and anchors at tissue lesions, enhancing cell recruitment, tissue repair, and regeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If extracellular vesicles are administered for tissue damage treatment, then therapeutic effect is provided, but integration and targeting efficiency remains low
Solution Approach 1:
The patent uses heparan sulfate as an intermediary substance that naturally bridges extracellular vesicles and tissue lesions. The vesicles are engineered to display heparan sulfate on their surface, allowing them to specifically bind to heparan sulfate proteoglycans at the lesion site, thereby mediating targeted delivery and improving both therapeutic efficacy and integration efficiency
Solution Approach 2:
The patent modifies the surface properties of extracellular vesicles by changing the concentration and configuration of heparan sulfate display on the vesicle surface. This parameter change enables the vesicles to optimize their binding affinity to tissue lesions while maintaining stability in circulation, thus resolving the contradiction between therapeutic effect and targeting efficiency
2Reliability
If repeated treatments are administered to improve integration efficiency, then therapeutic effect is enhanced, but treatment costs increase significantly
Solution Approach 1:
The patent implements preliminary action by pre-equipping extracellular vesicles with heparan sulfate display capabilities before administration. This preliminary modification ensures that the vesicles are ready to bind specifically to tissue lesions upon administration, eliminating the need for repeated treatments and thereby reducing overall treatment costs while maintaining therapeutic efficacy
3Reliability
If cell administration is performed for tissue repair, then tissue regeneration is promoted, but integration rate remains very low
Solution Approach 1:
The patent extracts the essential regenerative functions from whole cells and transfers them to extracellular vesicles. By isolating and encapsulating bioactive molecules within vesicles that display heparan sulfate, the patent achieves tissue regeneration effects without the integration problems associated with whole cell transplantation, thereby improving integration rate while maintaining tissue regeneration capability
Data Source
Figure 1(A)~1(B)
Figure 1(C)~2(A)
Figure 2(B)
AI summary
The present invention relates to a pharmaceutical composition comprising a biocompatible polymer of general formula (I) AaXxYy or (II) AaXxYyZz, and at least one extracellular vesicle. The present invention also relates to a method for preparing extracellular vesicles. The present invention has applications particularly in the therapeutic, pharmaceutical, and veterinary fields.